Interferon-alpha and c-phycocyanin for the treatment of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/21 (2006.01) A61K 31/40 (2006.01)

Patent

CA 2627531

The invention relates to a combination of interferon-alpha and C-phycocyanin (IFN-.alpha. / C-Phyco), which is used to obtain a pharmaceutical preparation for the treatment of autoimmune diseases, allergic diseases and cancer. The anti-inflammatory, immunomodulatory, antioxidant, antiviral, antiproliferative and antitumour effects which are associated with the inducing effect of regulatory T cells, which is shown in the invention, justify the use of the IFN-.alpha. / C-Phyco combination for said diseases.

La présente invention concerne la combinaison de l'interféron alfa et de la C-ficocianine (IFN-a / C-Fico) dans l'obtention d'une préparation pharmaceutique pour le traitement des maladies auto-immunes, des allergies et du cancer. Les effets anti-inflammatoires, immunomodulateurs, antioxydants, antiviraux, antiprolifératifs et antitumoraux, associés à l'effet inducteur des lymphocytes T régulatrices présenté dans cette invention, justifient l'utilisation de la combinaison IFN-a / C-Fico dans lesdites maladies.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Interferon-alpha and c-phycocyanin for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interferon-alpha and c-phycocyanin for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon-alpha and c-phycocyanin for the treatment of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1449058

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.